Test drug safety for early Alzheimer’s memory trouble
Part of Brain & nervous system, Mental health clinical trials.
This Phase 1 trial tests how safe and tolerable ALN-APP is in people with early Alzheimer’s-related mild memory impairment or mild dementia. It may help researchers find a treatment path for early Alzheimer’s, while closely monitoring side effects and basic health markers.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have mild cognitive impairment or mild dementia caused by early Alzheimer’s disease (EOAD)
- Your dementia stage scores are CDR global 0.5 or 1.0
- Your memory test score (MMSE) is above 20
- You do not have dementia caused by non-Alzheimer’s diseases
- Your liver and kidney labs are within limits (ALT/AST not more than 2x normal; eGFR at least 45)
- You have not recently taken an investigational drug or had an amyloid-targeting antibody
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an experimental drug called LY3439539 in people with early-stage Alzheimer's disease. The drug is designed to target protein changes in the brain that may slow memory loss and cognitive decline.
This early-stage trial tests whether ABBV-1758, a new drug given by injection, is safe and effective for people with Alzheimer's disease. The drug targets amyloid, a protein that builds up in the brains of people with Alzheimer's.
This trial tests a new investigational drug, BMS-986446, given as a single dose to healthy volunteers and multiple doses to people with early Alzheimer's disease. It aims to understand how the drug moves in the body, its safety, and whether it triggers an immune response, which could help guide future treatment for Alzheimer's.
This study tests an experimental drug called RO7568282 for people in the early stages of Alzheimer's disease. The goal is to see if it is safe and whether it can slow down memory loss and thinking problems.
This trial tests an investigational drug called ALN-5288 for people with Alzheimer's disease. It aims to see if the drug is safe and how it affects the body.
This study tests an investigational drug called BEY2153 for people with early Alzheimer's disease. It aims to see if the drug is safe and can help slow memory decline.
Hear when a new Early-Onset Alzheimer Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.